Cellectar Biosciences Files 8-K on Operations
Ticker: CLRB · Form: 8-K · Filed: Aug 14, 2025 · CIK: 1279704
| Field | Detail |
|---|---|
| Company | Cellectar Biosciences, Inc. (CLRB) |
| Form Type | 8-K |
| Filed Date | Aug 14, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-condition, operations
TL;DR
Cellectar Biosciences filed an 8-K on Aug 14, 2025, updating on financials and operations. Details inside.
AI Summary
Cellectar Biosciences, Inc. filed an 8-K on August 14, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company incorporated in Delaware and headquartered in Florham Park, NJ. The filing does not contain specific financial figures or operational details within the provided text.
Why It Matters
This 8-K filing provides an update on Cellectar Biosciences' operational and financial status, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — The filing is a standard 8-K reporting operational and financial information, not indicating any immediate or significant risks.
Key Players & Entities
- Cellectar Biosciences, Inc. (company) — Registrant
- August 14, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Florham Park, NJ (location) — Address of principal executive offices
- NOVELOS THERAPEUTICS, INC. (company) — Former company name
- COMMON HORIZONS INC (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Cellectar Biosciences, Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on August 14, 2025.
In which state is Cellectar Biosciences, Inc. incorporated?
Cellectar Biosciences, Inc. is incorporated in Delaware.
What is the principal executive office address for Cellectar Biosciences, Inc.?
The principal executive office address is 100 Campus Drive, Florham Park, NJ, 07932.
Has Cellectar Biosciences, Inc. operated under any former company names?
Yes, Cellectar Biosciences, Inc. has operated under the former company names NOVELOS THERAPEUTICS, INC. and COMMON HORIZONS INC.
Filing Stats: 453 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2025-08-14 07:30:37
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share CLRB The Nasdaq Capital M
Filing Documents
- tm2523504d1_8k.htm (8-K) — 26KB
- tm2523504d1_ex99-1.htm (EX-99.1) — 90KB
- tm2523504d1_ex99-1img001.jpg (GRAPHIC) — 4KB
- 0001104659-25-078102.txt ( ) — 292KB
- clrb-20250814.xsd (EX-101.SCH) — 3KB
- clrb-20250814_lab.xml (EX-101.LAB) — 33KB
- clrb-20250814_pre.xml (EX-101.PRE) — 22KB
- tm2523504d1_8k_htm.xml (XML) — 3KB
02
Item 2.02. Results of Operations and Financial Condition. On August 14, 2025, we issued a press release announcing our financial results for the quarter ended June 30, 2025, and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Number Title 99.1 Press release dated August 14, 2025, titled "Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update" 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CELLECTAR BIOSCIENCES, INC. Date: August 14, 2025 By: /s/ Chad J. Kolean Name: Chad J. Kolean Title: Chief Financial Officer